Pharmaceutical and Biotechnology Industry Watch: Innovative Drugs and Medical Devices Fuel a Structured Market Rally; AI in Healthcare Opens Up New Growth Opportunities

Release time：

2025-03-01

During the third week of February 2025, the pharmaceutical and biotechnology sector continued to exhibit structural divergence. Over the week, the pharmaceutical and biotechnology index rose by 1.88%, outperforming both the CSI 300 Index and the Shanghai Composite Index, ranking ninth in terms of sector performance.

During the third week of February 2025, the pharmaceutical and biotechnology sector continued to exhibit structural divergence. Over the week, the sector index rose by 1.88%, outperforming both the CSI 300 Index and the Shanghai Composite Index, ranking ninth in terms of sector performance. Among sub-sectors, medical R&D outsourcing led gains with a 11.3% increase, while offline pharmacies posted a 3.06% decline, making them the worst-performing sub-sector. On the valuation front, the current price-to-earnings ratio (TTM) stands at 26 times, remaining near a decade-low. Market capital continues to flow into hard-tech areas such as innovative drugs and AI-driven healthcare, and positive policy signals have further strengthened expectations for a bottom reversal in the sector.

Despite the broad prospects for AI in healthcare, its development continues to face challenges such as data compliance and lengthy clinical validation cycles. Currently, the market is increasingly focused on midstream platform companies in the “AI + Healthcare” space, which can rapidly translate technological advances into real-world applications by integrating algorithms, data, and clinical resources. At the same time, emerging technologies such as stem cell therapy and gene editing are beginning to demonstrate synergistic effects with AI, potentially becoming key competitive arenas in the next phase of industry development. Notably, striking a balance between the pace of technological iteration and regulatory adaptability will be a critical determinant of the industry’s growth trajectory.